Herbalife has announced plans to acquire assets from Bioniq, a London-based startup specializing in personalized supplement formulas derived from blood biomarker data. The deal is valued at up to $150 million, with a guaranteed purchase price of $55 million paid over five years, starting with an initial $10 million at closing. An additional $95 million is contingent on future performance milestones. This acquisition aligns with Herbalife’s strategy to address the personalization trend in the supplement industry. The transaction is set to close in Q2 2026, subject to regulatory approvals.
Founded in 2019 by Vadim Fedotov, Bioniq creates tailored supplement regimens using blood biomarker data and health questionnaires. Post-acquisition, Fedotov and key staff will join Herbalife’s leadership team. Previously, Bioniq raised $15 million in a Series B funding round in July 2024, and its valuation increased to $82 million after investments from Cristiano Ronaldo and Diogo Dalot.
The acquisition supports Herbalife’s focus on personalization and provides access to Bioniq’s algorithm and formulation expertise. Herbalife also secured an option to acquire Bioniq LAB for potential expansion into small molecules and peptides. Bioniq’s personalized supplements are expected to launch through Herbalife’s distributor network in European and US markets later this year.